Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | VP, Corporate Controller | August 10, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lyell Immunopharma, Inc.
Report date August 10, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,799 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Sale · Disposed 621 · Balance 14,799 F1: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. F2: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.20 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
F2: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.20 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 11, 2026 20:21 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 621 | $14.34 | $8,905.14 |
DisclosureSEC source: 0002095702-26-000005 · form4-08112026_080848.xml · nonDerivative · entry 1 Bulis Veronica Sanchez · CIK 0002095702 · VP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,799 F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.20 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| May 11, 2026 Filed Jun 15, 2026 22:32 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 217 | $18.91 | $4,103.47 |
DisclosureSEC source: 0002095702-26-000004 · form4-06152026_100616.xml · nonDerivative · entry 1 Bulis Veronica Sanchez · CIK 0002095702 · VP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,420 F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 02:00 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 254 | $23.12 | $5,872.48 |
DisclosureSEC source: 0002095702-26-000002 · form4-02122026_020223.xml · nonDerivative · entry 2 Bulis Veronica Sanchez · CIK 0002095702 · VP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,637 F2 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 02:00 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0002095702-26-000002 · form4-02122026_020223.xml · nonDerivative · entry 1 Bulis Veronica Sanchez · CIK 0002095702 · VP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,891 F1 · shares: Represents restricted stock units granted under the Issuer's 2021 Equity Incentive Plan. 12.5% of the total number of restricted stock units will vest on August 9, 2026, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date. Read SEC document |
| December 30, 2025 Filed Jan 6, 2026 21:02 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 936 | $32.32 | $30,251.52 |
DisclosureSEC source: 0002095702-26-000001 · form4-01062026_090153.xml · nonDerivative · entry 2 Bulis Veronica Sanchez · CIK 0002095702 · VP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,141 Read SEC document |
| December 24, 2025 Filed Jan 6, 2026 21:02 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 1,136 | $38.67 | $43,929.12 |
DisclosureSEC source: 0002095702-26-000001 · form4-01062026_090153.xml · nonDerivative · entry 1 Bulis Veronica Sanchez · CIK 0002095702 · VP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,077 F1 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $38.6643 to $38.6751 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 01:34 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 239 | $16.10 | $3,847.90 |
DisclosureSEC source: 0002095702-25-000003 · form4-11132025_011155.xml · nonDerivative · entry 1 Bulis Veronica Sanchez · CIK 0002095702 · VP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,213 F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $16.08 to $16.11 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.